concentrations than prescribed and can also lead to an elevation in nitrogen dioxide (NO2) levels. We have shown that calcium (Ca) absorption systems can scavenge NO2 and wanted to test if lithium (Li) systems could do the same. Methods: Our bench model consisted of a Michigan Lung (2 patient configurations: infant: 7 kg/ Compliance 0.08 L/cmH2O and toddler: 12 kg/compliance 0.15 L/cmH2O) connected to a Draeger Apollo delivery system with NO injector in the inspiratory limb at the Apollo. NO was delivered at doses of 20 and 40 ppm with each patient condition and appropriate ventilator settings (infant: Vt 60 mL, Ti 0.5; toddler: Vt 95 mL, Ti 0.7. Both had PEEP 5 cmH2O, IMV 25, FiO2 0.5). Relative FGF (rFGF) were varied over a range of 0.5 to 3 times minute ventilation. NO and NO2 were measured at 6 inches post injector module and in the inspiratory limb just prior to the patient wye with each patient condition and rFGF. Measurements were repeated with Ca and Li absorption systems, and under 'toddler' conditions without absorption canister for comparison. Results: Both Ca and Li absorbers were able to scavenge NO2 with the highest measured concentration of 3.2 ppm (5 ppm is the recommended upper limit) at an NO dose of 40 ppm. rFGF at 1.0 was sufficient to minimize NO2 with higher rFGF of no benefit. An rFGF of 1.5 was sufficient to make the measured NO match the set dose. NO and NO2 concentrations were slightly higher (by < 2 ppm) measured near the patient wye. Interestingly, NO concentrations at low rFGF were higher with absorbers in-line. Conclusions: iNO can be safely delivered via an anesthesia machine as long as there is adequate fresh gas flow. Ca and Li absorbers are equivalent in their abilities to scavenge NO2.
THE CASE OF THE VANISHING LUNG

Biplab Saha, Barry Kreiswirth, Kristin Fless
Learning Objectives: Staphylococcus aureus (SA) is a rare cause of community acquired pneumonia(CAP) and a major cause of influenza related mortality and morbidity. Necrotizing pneumonia due to Panton Valentin leucocidin (PVL) toxin secreting strains of S. aureus is associated with a mortality rate of up to 40-60%. Both methicillin resistant (MRSA) and methicillin sensitive S. aureus (MSSA) can carry gene for PVL toxin. Methods: A sixty-three year old female with a history of asthma, who had lost her husband 1 week ago from pneumonia, presented to the emergency room with a fever, generalized malaise, nasal discharge, cough, sputum production and shortness of breath for 3 days. Blood work demonstrated leukocytosis with bandemia. Chest X-Ray showed bilateral infiltrates. She was treated for CAP with Ceftriaxone and Azithromycin. Blood culture grew MSSA. She received nafcillin but her condition deteriorated. She required high flow 100% oxygen. Chest CT scans done 7 days apart showed blossoming bilateral infiltrate and development of multiple cavitary lesions of the lung. She was started on Linezolid, Clindamycin and intravenous immunoglobulin (IVIG) for suspected necrotizing pneumonia with PVL toxin producing MSSA. She underwent extra corporeal membrane oxygenation with subsequent recovery. The genetic study confirmed PVL gene consistent with MRSA USA 300. Results: PVL toxin causes lysis of the neutrophil with release of pro-inflammatory cytokines. Influenza like prodrome, leukopenia, thrombocytopenia, hemorrhage and pleural effusion are indicators of fatal outcome. Clindamycin and Linezolid have antitoxin effect and may improve clinical outcome. IVIg has also been used with some success. In the U.K. routine testing is done as most European PVL strains are MSSA, however it is not recommended in the U.S. Conclusions: The suspicion of PVL toxin producing SA strain as a cause of necrotizing pneumonia is extremely important. Early initiation of treatment with appropriate antibiotics directed at the toxin and IVIG might be lifesaving. Checking for PVL toxin may help in early determination of a fatal pathogen.
HIGH DOSE OSELTAMIVIR AND ARDS ADJUNCT THERAPY IN SEVERE INFLUENZA: A COMPARISON OF TWO OUTBREAKS
Miguel Franquiz, Jeffrey Gonzales, Paul Saleeb, Carl Shanholtz Learning Objectives: 2009 influenza A H1N1 virus was the predominant isolate identified by influenza surveillance during 2009-2010 and 2013-2014, causing significant morbidity and mortality during these outbreaks. Several organizations recommend the use of high dose oseltamivir for critically ill patients with severe influenza, despite minimal supporting evidence. The objective of this study was to evaluate the use of oseltamivir and ARDS adjunct therapies in critically ill patients across two severe influenza outbreaks. Methods: Single center, retrospective study of patients admitted to the ICU receiving oseltamivir for the treatment of influenza during peak outbreak periods, based on influenza related hospitalization data reported to the Influenza Hospitalization Network. Demographics, comorbidities, and APACHE II scores were abstracted from the medical record. Primary outcomes included use of oseltamivir and ARDS adjunct therapies. Secondary outcomes include: complications of influenza (ARDS, sepsis, coinfection, AKI), length of stay, duration of mechanical ventilation, and mortality. Descriptive analysis is presented for the total population across both influenza seasons. Results: 124 patients were included (n=53, 2009; n=71, 2013) Demographics were: age 52.3 ± 14.2 yr, APACHE II score 19.4 ± 9.2, 71% had ≥2 comorbidities, and 27% died. Use of high dose oseltamivir decreased by 54% [n=18 (31%), 2009; n=11 (15%), 2013, p=0.02]. Inhaled nitric oxide was more prevalent in 2009 (p=0.001), while neuromuscular blockade, and inhaled prostacyclin were more prevalent in 2013 (p<0.05). There was no difference in prone positioning or HFOV. No differences in complications of influenza, with the exception of an increase in AKI in the 2013 patients (p=0.02). No difference in length of stay, duration of mechanical ventilation, or mortality was observed. Conclusions: The use of high dose oseltamivir decreased across the 2009 and 2013 outbreaks. ARDS adjunct therapy changed significantly since 2009. These findings likely represent evidenced-based changes in practice. Mortality was similar across the 2009 and 2013 outbreaks.
DEAD SPACE SURROGATES FROM ROUTINE CLINICAL DATA IN CRITICALLY ILL CHILDREN
Anoopindar Bhalla, Christopher Newth, Robinder Khemani
Learning Objectives: High dead space measured by capnography is consistently associated with increased mortality in mechanically ventilated adults and children. However capnography data is rarely available in existing databases of mechanically ventilated patients. This has limited our ability to assess the use of dead space for risk stratification. Alternative methods using available clinical data to evaluate dead space have been suggested. We sought to investigate the correlation between volumetric capnography measured physiologic dead space and two proposed dead space surrogates. Methods: Mechanically ventilated children with arterial lines were monitored with volumetric capnography. We calculated at the time of arterial blood gas 1) physiologic dead space from volumetric capnography (Vd/ Vt(volcap) = (PaCO2-mean expired PCO2)/PaCO2) 2) corrected minute ventilation (VEcorr =((minute ventilation x PaCO2)/40)/kg) and 3) physiologic dead space from the rearranged alveolar gas equation (Vd/Vt(ag)= 1-(0.86 x VCO2)/ (minute ventilation x PaCO2) where VCO2 is estimated CO2 production using calculated energy expenditure). Results: We enrolled 65 children (52% male) with a median age of 4.9 yr (interquartile range (IQR) 1.7, 12.8). The children had a median Vd/Vt(volcap) of 0.51 (IQR 0.45, 0.60), median VEcorr of 0.18 L/ min/kg (IQR 0.13, 0.22) , and median Vd/Vt(ag) of 0.37 (IQR 0.20, 0.49) . The correlation between Vd/Vt(volcap) and VEcorr was moderate (r2=0.46). The correlation between Vd/Vt(volcap) and Vd/Vt(ag) was poor (r2=0.28). Conclusions: Dead space surrogates calculated using available clinical data have moderate to poor correlation with capnography measured dead space in critically ill children. Further research should focus on their ability to stratify mortality risk before they are used as substitutes for capnography measures of dead space.
CHILDREN AT RISK FOR PEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME REQUIRING HIGH FLOW NASAL CANNULA
Katherine Slain, Natalia Martinez-Schlurmann, Anne Stormorken, Steven Shein Learning Objectives: New definitions of pediatric acute respiratory distress syndrome (PARDS) were recently published, including criteria to identify children "at risk for PARDS." Such children may have acute respiratory failure treated with high flow nasal cannula (HFNC), an increasingly prevalent support modality. We hypothesized that among bronchiolitis patients on HFNC, those "at risk for PARDS" would have longer PICU and hospital length of stay (LOS), and increased duration of HFNC and supplemental oxygen. Methods: We retrospectively reviewed the
